News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Clinical - Phase III
AEterna Zentaris (AEZS): Data And Safety Monitoring Board Recommends Continuation Of ZoptEC Phase 3 Trial In Advanced Endometrial Cancer 10/13/2015
Shire (SHPG)'s CINRYZE Receives FDA Fast Track Designation 10/13/2015
Radius Health (RDUS) Release: Investigational Drug Abaloparatide Reduces The Incidence Of Fractures In Postmenopausal Women With Osteoporosis 10/13/2015
Dermira Completes Patient Enrollment For First CIMZIA (Certolizumab Pegol) Phase III Clinical Trial In Psoriasis Program 10/13/2015
Eli Lilly (LLY)'s CETP Failure a Bad Sign for Merck & Co. (MRK)’s Anti-Cholesterol Drug Anacetrapib 10/13/2015
Amgen (AMGN) Release: New Data Show Consistent Safety Profile For Up To 10 Years With Prolia (Denosumab) In Postmenopausal Women With Osteoporosis 10/13/2015
BASF To Develop A High Purity Poloxamer For Mast Therapeutics (MSTX) 10/13/2015
Motif Bio plc Announces Results Of Two Posters On Iclaprim At ID Week 2015 10/13/2015
Portola (PTLA) Announces FDA Grants Fast Track Designation To Betrixaban For Prevention Of Blood Clots In Acute Medically Ill Patients 10/13/2015
TherapeuticsMD, Inc.  (TXMD) Completes Enrollment In Phase 3 Clinical Trial Of Bio-Identical Oral Combination Of Estradiol And Progesterone Product Candidate 10/13/2015
Aradigm Corporation (ARDM) Completes Enrollment In The Second Phase III Study Of Pulmaquin In Non-Cystic Fibrosis Bronchiectasis (ORBIT-3) 10/13/2015
Can-Fite BioPharma (CFBI) Announces $4.8 Million Registered Direct Offering 10/13/2015
Eli Lilly (LLY) Stock Falls 10 Percent After Company Halts Late-Stage Cholesterol Drug 10/12/2015
European Medicines Agency Grants Orphan Designation To Can-Fite BioPharma (CFBI)'s CF102 In The Treatment Of Liver Cancer 10/12/2015
Eli Lilly (LLY) Acquires Phase III Intranasal Glucagon From Locemia Solutions 10/12/2015
Allergan (AGN) Release: Data Presented at IDWeek Reports AVYCAZ (ceftazidime and avibactam) Demonstrated In Vitro Antimicrobial Activity Against Common Enterobacteriaceae Pathogens, Including Certain Carbapenem-Resistant Strains 10/12/2015
Melinta Presents Complete Delafloxacin Results From Phase III Study In Patients With Acute Bacterial Skin And Skin Structure Infections At ID Week 10/12/2015
Radius Health (RDUS) Presents Positive Phase 3 Top-Line Data For Investigational Osteoporosis Therapy Abaloparatide At The American Society For Bone And Mineral Research 2015 Annual Meeting 10/12/2015
Spark Therapeutics (ONCE) Announces Presentation Of Additional Phase 3 And Durability Data On SPK-RPE65 At The Retina Society 48th Annual Scientific Meeting 10/12/2015
Celgene (CELG) Release: One Year Data From Phase III Study Evaluating Oral OTEZLA (Apremilast) Or Injectable Etanercept Versus Placebo In Patients With Moderate To Severe Plaque Psoriasis Presented At EADV 10/12/2015
Neurocrine Biosciences (NBIX)'s NBI-98854 Hits Primary Enpoint in Phase III Study 10/9/2015
Amgen (AMGN) Fights Fire with Fire in the Biosimilars Market 10/9/2015
Nektar Therapeutics (NKTR) Reports On Advancements With Pain And Oncology Clinical Pipeline At Investor And Analyst R&D Day 10/9/2015
AcelRx (ACRX) Announces Presentation Of Phase 3 Sufentanil Sublingual 30mcg Tablet Data At The European Society Of Emergency Medicine Meeting 10/9/2015
Allergan (AGN) Release: FDA Accepts Supplemental New Drug Application (sNDA) for DALVANCE (dalbavancin) 10/9/2015
Norgine Release: Positive Phase III Top Line Results Demonstrate Efficacy Of NER1006, A Novel, Low Volume Bowel Preparation, Vs. Trisulfate 10/9/2015
Lexicon Pharma (LXRX) Announces Telotristat Etiprate Data To Be Presented At North American Neuroendocrine Tumor Society Annual Symposium 10/9/2015
Aimmune (AIMT) Announces COO Transition 10/9/2015
Exelixis (EXEL), Genentech (RHHBY)'s Cobimetinib Succeeds in Pivotal Phase III Trial 10/8/2015
OncoGenex (OGXI) Announces European Medicines Agency Support For Phase 3 AFFINITY Trial Protocol Amendment 10/8/2015
Allergan (AGN) Anti-Infective Portfolio Highlighted In 13 Abstracts At IDWeek 2015 10/8/2015
CoLucid Pharma (CLCD) Announces Initiation Of Phase III Long-Term, Open-Label Trial Of Lasmiditan In Migraine 10/8/2015
AcelRx (ACRX) Provides Regulatory Update On Zalviso 10/8/2015
Genentech (RHHBY)’s Ocrelizumab First Investigational Medicine To Show Positive Pivotal Study Results In Both Relapsing And Primary Progressive Forms Of Multiple Sclerosis 10/8/2015
TauRx Completes $135 Million Funding Round to Support Phase III Trials for Key Products 10/8/2015
Biogen (BIIB) Release: Results From ZINBRYTA (Daclizumab High-Yield Process) Phase 3 DECIDE Study Highlighting Efficacy Compared To Interferon Beta-1a Published In The New England Journal Of Medicine And Presented At ECTRIMS 10/8/2015
Tenax Therapeutics (TENX) Provides Clinical Update For Lead Candidate Levosimendan 10/8/2015
30-Year-Old Hedge-Fund Whiz Kid’s Axovant (AXON) Starts Alzheimer’s Phase III Trial 10/7/2015
Clal Biotech (CLALF) Opts Out of Re-Acquiring Andromeda from Hyperion (HPTX) After Phase III Diabetes Drug Tanks 10/7/2015
Can-Fite BioPharma (CFBI) To Deliver 2 Presentations On Its Cancer Drug CF102 At The 20th World Congress On Advances In Oncology And 18th International Symposium On Molecular Medicine On October 8-10, 2015 In Athens 10/7/2015
Immune Pharmaceuticals, Inc. Submits Investigational New Drug Application (IND) In The U.S. For Its Lead Product Candidate Bertilimumab For The Treatment Of Bullous Pemphigoid 10/7/2015
Biogen (BIIB) Release: New Data Show Strong, Sustained Effects Of TECFIDERA (Dimethyl Fumarate) In Newly-Diagnosed And Early Disease Course Multiple Sclerosis Patients 10/7/2015
Sanofi Genzyme (SNY) New Analysis Suggests Aubagio (teriflunomide) Slows Brain Atrophy In People With Relapsing Multiple Sclerosis 10/7/2015
Spark Therapeutics (ONCE) Soars as Eye Drug Hits Goals in Pivotal Phase III Study 10/6/2015
AcelRx (ACRX) Announces Initiation Of Clinical Study With ARX-04 In Emergency Room Patients With Moderate-To-Severe Acute Pain 10/6/2015
Vaccinogen Appoints Michael G. Hagerman To Its Board Of Directors 10/6/2015
Aytu BioScience Acquires Second Revenue-Generating Urology Product 10/6/2015
Catalyst Pharmaceuticals (CPRX) Announces A Clinical Trial For Pediatric Patients With Congenital Myasthenic Syndromes 10/6/2015
Active Biotech (BTPC)'s Partner Teva (TEVA) Presents Data On Laquinimod For The Treatment Of Multiple Sclerosis At 31st ECTRIMS Congress 10/6/2015
Amgen (AMGN) To Give 23 Presentations On Osteoporosis Disease And Treatment At American Society For Bone And Mineral Research Annual Meeting 10/6/2015
Portage Biotech's Biohaven Completes Multiple Dose Phase Of Pharmacokinetic Trial With BHV-0223 10/6/2015
Celsion (CLSN) Announces Upcoming Presentations At The 2nd Asian Conference On Tumor Ablation On October 30-31, 2015 10/6/2015
Eli Lilly (LLY) To Showcase Data For Investigational Psoriasis Treatment At 24th European Academy Of Dermatology And Venereology Congress 10/6/2015
Osiris Therapeutics, Inc. (OSIR) Announces Initiation Of A Phase III Trial For A New Investigational Drug, OTI-15-01, For The Treatment Of Chronic Diabetic Foot Wounds 10/6/2015
Teva (TEVA) Reinforces Focus On Advancing Multiple Sclerosis Treatment At 31st ECTRIMS Congress 10/6/2015
Akebia Therapeutics, Inc. (AKBA) Reaches Agreement With FDA And European Medicines Agency On Vadadustat Global Phase III Program 10/6/2015
Infinity Pharmaceuticals Inc. (INFI) To Provide Update On Duvelisib And Immuno-Oncology Development Candidate IPI-549 During 2015 Research And Development Day 10/6/2015
Results From Merck & Co. (MRK)’s Phase 3 Study Of Investigational Chronic Hepatitis C Therapy Elbasvir/Grazoprevir In Patients With Advanced Chronic Kidney Disease Published In Lancet 10/6/2015
Astex Pharmaceuticals (ASTX) Announces Orphan Drug Designation For Guadecitabine (SGI-110) In The Treatment Of Acute Myeloid Leukemia 10/6/2015
Coherus' CHS-1701 Met Primary PD Endpoint in Phase III Study 10/5/2015
Oncobiologics Announces ONS-1045 (Avastin/bevacizumab biosimilar) Meets Primary And Secondary Endpoints In Phase 1 Clinical Trial 10/5/2015
ContraVir Pharmaceuticals Reports New Data Demonstrating CMX157 To Be 60-Fold More Potent Against Hepatitis B Virus Than Gilead (GILD)'s Viread 10/5/2015
Cempra Pharmaceuticals, Inc. (CEMP) To Present Solithromycin Data At ID Week 2015 10/5/2015
AbbVie (ABBV) Demonstrates Leadership In Dermatology With 26 Abstracts At The European Academy Of Dermatology And Venereology Congress 10/5/2015
Foundation Fighting Blindness Applauds Phase 3 Study Results For Investigational Gene Therapy Treatment 10/5/2015
Onxeo Announces Positive DSMB Recommendation For Continuation Of Livatag Relive Study In HCC 10/5/2015
ErgoMed Increases Its Co-Development Contribution Up To $12,000,000 In CEL-SCI (CVM)’s Phase III Head And Neck Cancer Trial 10/5/2015
AbbVie (ABBV) Demonstrates Commitment To Hepatitis C Patients With New Data On VIEKIRA PAK (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) And Ongoing Clinical Development Program At The Liver Meeting 2015 10/2/2015
Clinical Data From Merz Neurosciences’ Phase III Extension Study Of XEOMIN (Incobotulinumtoxina) For Spasticity To Be Presented At 2015 AAPM&R Annual Meeting 10/2/2015
Strong Data Shows that Cambridge's Sarepta (SRPT) May Earn Approval of Duchenne Drug 10/1/2015
CEL-SCI (CVM) Reports September Patient Enrollment For Its Phase III Head And Neck Cancer Trial 10/1/2015
BioCancell Advances Phase III Clinical Program For Bladder Cancer 10/1/2015
Novartis AG (NVS) Announces The New England Journal of Medicine Publication Of secukinumab Phase III Data Confirming Significant Efficacy In Patients With Psoriatic Arthritis 10/1/2015
CTI BioPharma And Fred Hutchinson Cancer Research Center Announce International Research Fellowship To Support Innovative Blood-Related Cancer Research 10/1/2015
RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives $500,000 Milestone Payment With Enrollment Of First Patient In U.S. Phase 2b/3 Dry Eye Trial 10/1/2015
Orexigen (OREX) Announces Submission Of Contrave New Drug Application In South Korea 10/1/2015
Dipexium Pharmaceuticals (DPRX) Reaches 50% Enrollment In Second Pivotal Phase 3 Clinical Trial 10/1/2015
BioMarin (BMRN) To Present Research Results On Duchenne Muscular Dystrophy And Pompe Disease Programs At The 20th International Congress Of The World Muscle Society 10/1/2015
Versartis, Inc. (VSAR) Presents Confirmatory 18-Month Data From Ongoing Somavaratan Extension Study At Late-Breaker Session At ESPE Annual Meeting 10/1/2015
The Medicines Company (MDCO) Announces Participation At IDWeek 2015 Meeting 10/1/2015
BiondVax Pharmaceuticals Establishes Capability For The Manufacture Of Clinical Grade Universal Flu Vaccine For Phase III Clinical Trials 10/1/2015
Eli Lilly (LLY), Incyte (INCY) Rheumatoid Arthritis Drug Succeeds in Phase III Trial 9/30/2015
OXiGENE (OXGN) Announces Plans To Advance CA4P (Fosbretabulin) In Two Late-Stage Clinical Trials 9/30/2015
PTC Therapeutics (PTCT) Submits European Application For Translarna For Cystic Fibrosis 9/30/2015
Bellerophon Therapeutics (BLPH) Announces Functional Respiratory Imaging Data From Company Sponsored Clinical Trial Of Inopulse In COPD Patients With Pulmonary Hypertension Presented Today At The European Respiratory Society (ERS) International Congress 9/30/2015
Data Supporting Delcath Systems (DCTH)'s Chemosat System Presented At The Cardiovascular and Interventional Radiology Society Annual Meeting 9/30/2015
Genentech (RHHBY) May Have a $5 Billion MS Blockbuster on Its Hands 9/29/2015
Genentech (RHHBY)’s ORATORIO Trial Meets Primary Endpoint in Phase III; FDA Data Submission Planned for 2016 9/29/2015
Esperion (ESPR) Stock Plummets as Updates on ETC-1002 Prove Not Enough for Investors 9/29/2015
Sanofi (SNY) New Drug Application For Lixisenatide Accepted For Review By FDA 9/29/2015
Lexicon Pharma (LXRX)'s Telotristat Etiprate Shows Clinical Benefit In Treating Carcinoid Syndrome In Cancer Patients When Added To Standard Of Care 9/29/2015
Revance Therapeutics (RVNC) Initiates Phase III Clinical Trial Of Botulinum Toxin Type A Topical Gel To Treat Lateral Canthal Lines 9/29/2015
Boehringer Ingelheim Release: New Data Shows OFEV (nintedanib) Efficacy Is Sustained Long-Term With No New Safety Signals In Patients With IPF 9/29/2015
New Roche (RHHBY) Esbriet Data Show Clinical Benefits Of Continued And Long-Term Treatment In Patients With Idiopathic Pulmonary Fibrosis (IPF) 9/29/2015
Ablynx (ABLYF) Initiates A Multinational Phase III Study With Caplacizumab In Patients With Acquired TTP, A Rare Blood Clotting Disorder 9/29/2015
Can-Fite BioPharma (CFBI) To Present CF101 Psoriasis Data At Late Breaking Session Of The EADV Congress In Copenhagen On October 10, 2015 9/29/2015
Anaconda Pharma Announces Presentations Of Crisaborole Topical Ointment, 2% Phase 3 Pivotal Data At Two Upcoming Medical Conferences 9/29/2015
Anacor (ANAC) Announces Presentations Of Crisaborole Topical Ointment, 2% Phase III Pivotal Data At Two Upcoming Medical Conferences 9/29/2015
GlaxoSmithKline (GSK) Presents Post-Hoc Analysis Of Anoro Ellipta Data Assessing Markers Of COPD Deterioration Compared To Tiotropium Or Placebo Using A Novel Composite Endpoint 9/29/2015
OncoGenex (OGXI) Presents Additional Phase 3 SYNERGY Analyses Showing Custirsen Significantly Reduced Serum Clusterin Levels In Metastatic Prostate Cancer Patients; Low Levels Correlate With Improved Survival In Those At Increased Risk For Poor Outcomes 9/28/2015
Vtesse, Inc. Initiates Phase 2b/3 Clinical Trial Of VTS-270 For Treatment Of Niemann-Pick Type C1 (NPC) Disease 9/28/2015
IMPAX Labs (IPXL) Receives Positive CHMP Opinion for NUMIENT (Levodopa And Carbidopa) Modified-Release Capsules For The Symptomatic Treatment Of Adult Patients With Parkinson's Disease 9/28/2015
Novartis AG (NVS) Drug Afinitor Significantly Improves Progression-Free Survival In Advanced Nonfunctional Gastrointestinal And Lung NET 9/28/2015
Eli Lilly (LLY)'s CYRAMZA (ramucirumab) Significantly Improves Progression-Free Survival In Phase II Bladder Cancer Trial 9/28/2015
Intercept Pharma (ICPT) Announces Initiation Of REGENERATE Trial For Obeticholic Acid In NASH Patients With Advanced Liver Fibrosis 9/28/2015
Vital Therapies (VTL) Outlines Plans For New Phase 3 Trial Of ELAD In Alcohol-Induced Liver Decompensation 9/28/2015
Amgen (AMGN) Receives CHMP Positive Opinions For Two New Treatment Options For Patients With Blood Cancer In Europe 9/28/2015
Braeburn Announces FDA's Acknowledgment Of Receipt Of Probuphine NDA Resubmission; Agency Action Expected By February 27, 2016 9/28/2015
Advanced Accelerator Applications Announces Positive Results From Phase 3 Study NETTER-1 Evaluating Lutathera In Patients With Advanced Midgut Neuroendocrine Tumors 9/28/2015
Array BioPharma, Inc. (ARRY) Release: Clinical Data Presented On Binimetinib And Encorafenib In Melanoma 9/28/2015
Boehringer Ingelheim Release: New Head-to-Head STIOLTO RESPIMAT Data Presented At ERS Annual Congress 9/28/2015
Mast Therapeutics (MSTX) Announces Presentation Of Results Of Nonclinical Study Of Vepoloxamer In Chronic Heart Failure At The HFSA's Annual Scientific Meeting 9/28/2015
Media Alert: Lexicon Pharma (LXRX) To Discuss Complete Results Of Pivotal Phase 3 TELESTAR Study 9/28/2015
Exelixis (EXEL) Announces Positive Results From METEOR Phase 3 Pivotal Trial Of Cabozantinib In Advanced Renal Cell Carcinoma Presented At European Cancer Congress 2015 9/28/2015
Clinical Validity Of Molecular Profiling From Caris Life Sciences Confirmed By Study Demonstrating Increased Median Overall Survival And Clinical Impact On Treatment Decisions 9/28/2015
Boehringer Ingelheim Release: COPD: New Data Support Role Of Spiolto Respimat As 1st-Line Maintenance Therapy And Show Superiority Over LABA/ICS 9/28/2015
Heron (HRTX) Announces Oral Presentation Of Data From Completed Phase 3 MAGIC Study For SUSTOL At The ASCO Breast Cancer Symposium 9/28/2015
Bristol-Myers Squibb (BMY) Release: Opdivo (nivolumab) Demonstrates Long Term Survival Benefit In Patients With Previously Treated Non-Squamous Non-Small Cell Lung Cancer In Checkmate -057 9/28/2015
Teva (TEVA) Presents New Reslizumab Data At European Respiratory Society (ERS) International Congress 2015 9/28/2015
Boehringer Ingelheim Release: ECC 2015: GIOTRIF (Afatinib) Demonstrates Superior Survival Compared To Tarceva (Erlotinib) For Patients With Previously Treated Advanced Squamous Cell Carcinoma Of The Lung, Independent Of EGFR Mutation Status 9/28/2015
Boehringer Ingelheim Release: VARGATEF Plus Docetaxel Significantly Reduced Tumour Burden In Lung Cancer Patients With Advanced Adenocarcinoma Compared To Docetaxel Alone 9/28/2015
Puma Biotech (PBYI) Announces Presentation Of Phase III Trial Of PB272 In Extended Adjuvant Breast Cancer (Extenet Trial) In Centrally Confirmed HER2-Positive Early Stage Breast Cancer Patients 9/28/2015
Bristol-Myers Squibb (BMY) Release: Opdivo (nivolumab) Demonstrates Superior Overall Survival In A Phase 3 Trial Compared To Standard Of Care In Patients With Previously Treated Advanced Renal Cell Carcinoma 9/28/2015
Galapagos (GLPG.BR) To Advance Filgotinib To Phase 3 In Rheumatoid Arthritis 9/25/2015
Eisai Inc. (ESALF.PK) And Arena Pharmaceuticals, Inc. (ARNA) Announce Presentation Of Lorcaserin HCl Data At Upcoming Medical Meetings 9/25/2015
ImmunoCellular Therapeutics, Ltd (IMUC) Awarded $19.9 Million Grant From California Institute For Regenerative Medicine (CIRM) To Fund ICT-107 Phase 3 Registration Program In Glioblastoma 9/25/2015
Otonomy (OTIC)To Present Results For Auripro Phase III And OTO-104 Phase IIb Clinical Trials At 2015 AAO-HNSF Annual Meeting 9/24/2015
Cempra Pharmaceuticals, Inc. (CEMP) To Present Solithromycin Data In COPD Patient Subgroup At European Respiratory Society International Congress 9/24/2015
Caladrius Biosciences Receives Award From The National Cancer Institute 9/24/2015
OptiNose AS Announces Positive Results Of Second Phase III Pivotal Trial For OPN-375 9/24/2015
Mast Therapeutics (MSTX) To Host Analyst & Investor Day On October 7, 2015 9/24/2015
Resverlogix (RVX.TO) Announces The Commencement Of An Orphan Disease Program Specific For Complement Mediated Diseases 9/24/2015
Aerie (AERI) Initiates Fourth Phase III Clinical Trial of Rhopressa 9/24/2015
Amgen (AMGN) To Present New Kyprolis (carfilzomib) Data At 15th International Myeloma Workshop 9/24/2015
ABIVAX Completes Recruitment In Its Phase IIb/III Pivotal Study With ABX203, First-In-Class Therapeutic Vaccine Against Chronic Hepatitis B 9/24/2015
Ampio Pharmaceuticals, Inc. (AMPE) Receives Special Protocol Assessment (SPA) From The FDA And Commences Second Phase III Pivotal Trial Of Ampion 9/23/2015
More Than 50 Presentations Of New Data From Sanofi Genzyme (SNY)’s Multiple Sclerosis Franchise To Be Featured At ECTRIMS 9/23/2015
ViiV Healthcare Release: New Phase IIIb/IV Data Show Switching To Once-Daily Triumeq Maintains HIV Viral Suppression 9/23/2015
Amgen (AMGN) and Allergan (AGN)'s Avastin Copycat Succeeds in Late Stage Lung Cancer Study 9/23/2015
Gilead (GILD) Beats AbbVie (ABBV) Again 9/22/2015
Aradigm Corporation (ARDM) Completes Enrollment In Phase III Study Of Pulmaquin In Non-Cystic Fibrosis Bronchiectasis (ORBIT-4) 9/22/2015
AstraZeneca PLC (AZN) To Present Data Demonstrating Diversity Of Its Portfolio Of Innovative Formulations And Devices At The European Respiratory Society International Congress 2015 9/22/2015
Gilead (GILD) Reports Positive Update on Four Sofosbuvir Combo Phase IIIs in Certain HCV 9/21/2015
Paratek Pharmaceuticals, Inc.'s Omadacycline, Demonstrates Broad Spectrum Activity In Pathogens Relevant In Skin Infections, Community-Acquired Pneumonia And Urinary Tract Infections 9/21/2015
Hemispherx (HEB) Research Team Identifies Characteristics Of Chronic Fatigue Syndrome (CFS) Patients Potentially Predictive Of Improved Response To Ampligen 9/21/2015
Aerie (AERI) Initiates First Phase III Registration Trial Of Roclatan 9/21/2015
The Medicines Company (MDCO) Reports Discovery Of New Series Of Beta-Lactamase Inhibitors At ICAAC/ICC 2015 9/21/2015
RegeneRx Biopharmaceuticals, Inc. (RGRX) Announces First Patient Enrolled In Phase 3 U.S. Neurotrophic Keratopathy (NK) Clinical Trial With RGN-259 9/21/2015
Veloxis Pharmaceuticals A/S (VELO) Announces Publication Of Phase III-B STRATO Study Of Envarsus XR Demonstrating Reduction In Hand Tremors Compared To Twice-Daily Tacrolimus In Kidney Transplant Patients 9/21/2015
Merck & Co. (MRK) Touts Success of Two Late-Stage Trials for C. Diff Recurrence 9/21/2015
Versartis, Inc. (VSAR) Announces Confirmatory 18-Month Data From Ongoing Extension Study Of Somavaratan In GHD Children 9/18/2015
FORUM Pharma Halts Clinical Trials for Alzheimer’s and Schizophrenia Drug 9/17/2015
TG Therapeutics, Inc. (MHA) Announces Special Protocol Assessment (SPA) Agreement With The FDA For The First Phase 3 Clinical Trial Of Its Proprietary Combination Regimen Of TG-1101 (ublituximab) In Combination With TGR-1202 For Patients With Chronic Lymphocytic Leukemia (CLL) 9/17/2015
Paratek Pharmaceuticals, Inc.'s Omadacycline, Demonstrates Broad Spectrum Activity In Pathogens Relevant In Skin Infections, Community-Acquired Pneumonia And Urinary Tract Infections 9/17/2015
Cyclacel Pharmaceuticals, Inc. (CYCC) Presents Molecular Rationale For Clinical Development Of CYC065 CDK Inhibitor In Leukemias And Lymphomas 9/17/2015
FDA Grants Fast Track Designation To Can-Fite BioPharma (CFBI)'s CF102 In The Treatment Of Liver Cancer 9/17/2015
Merck & Co. (MRK) Provides Diabetes Portfolio Update And Underscores Comprehensive, Long-Term Commitment To Patients With Diabetes 9/17/2015
Aerie (AERI) Shares Soar After Glaucoma Drug Meets Late Stage Endpoints 9/17/2015
Intra-Cellular Therapies Surges as Schizophrenia Drug Met Primary Endpoint in Phase III 9/17/2015
Bristol-Myers Squibb (BMY) Grabs Breakthrough Tag for Opdivo 9/16/2015
Bellerophon Therapeutics (BLPH) Reshuffles Top Management and Reduces Costs to Move Nitric Oxide Therapy Through Late-Stage Clinical Trials 9/16/2015
Immune Pharmaceuticals, Inc. Announces Initiation Of Stock Purchase Plan With Up To $250,000 In Purchases By Its CEO 9/16/2015
Lipid Therapeutics Licenses Rights To Its Novel Therapy For Ulcerative Colitis To Nestlé Health Science 9/16/2015
AbbVie (ABBV) Announces Plans To Proceed To Phase 3 Evaluation Of Elagolix In Patients With Uterine Fibroids 9/16/2015
RegeneRx Biopharmaceuticals, Inc. (RGRX) Announces First Patients Enrolled In Phase 2b/3 U.S. Dry Eye Clinical Trial With RGN-259 9/16/2015
Intarcia Presents Results From Two Successful Phase 3 Trials For ITCA 650, Its Investigational Therapy In Type 2 Diabetes, At 51st EASD 9/16/2015
Innocoll (INNL) Announces First Patient Dosed In The Xaracoll MATRIX-2 Phase 3 Study For The Treatment Of Postoperative Pain 9/16/2015
Topica Pharmaceuticals Announces 10% Luliconazole Program Ready For Phase 3 Development For Onychomycosis Based On Positive Phase 2 Results 9/16/2015
Aytu BioScience To Present Study Data At The American Society for Reproductive Medicine's Annual Meeting 9/16/2015
Allergan (AGN) Anti-Infective Portfolio Highlighted In 24 Abstracts At ICAAC 2015 9/16/2015
CSL Limited (CMXHF.PK) Release: FDA Advisory Panel Recommends Licensure of NVS Influenza Candidate Vaccine for Protection Against Seasonal Influenza in the Elderly 9/16/2015
Analysts Bet Novo Nordisk A/S (NVO)'s Insulin Drug Will Get FDA Approval 9/15/2015
Sanofi (SNY) Plans LixiLan Filings After Meeting Phase III Primary Endpoint 9/15/2015
Avillion Announces Completion Of Enrolment In Phase III BFORE Trial To Assess BOSULIF (bosutinib) As First-Line Treatment For Patients With Chronic Myelogenous Leukemia 9/15/2015
NIH Awards $7.5 Million Grant For AgeneBio HOPE4MCI Phase 3 Clinical Trial To Delay The Onset Of Alzheimer's Dementia 9/15/2015
Health Canada Approves Amgen (AMGN)'s New Cholesterol-Lowering Medication Repatha (evolocumab) 9/15/2015
Makindus Bolsters Management Team With Appointment Of Michael Celano As Chief Financial Officer 9/15/2015
AZTherapies, Inc. Commences Phase III Pivotal Trial - For ALZT-OP1 In Early Alzheimer's Disease 9/15/2015
Portola Announces Second Part Of Phase 3 ANNEXA-R Study: Andexanet Alfa And Rivaroxaban Meets Primary And Secondary Endpoints 9/15/2015
FDA Draft Guidance Is Consistent With Evoke Pharma, Inc.'s Current Phase 3 Study Design And Endpoint For EVK-001 9/15/2015
BeyondSpring Announces Positive Follow-Up Results For Phase 2 Trial Of Plinabulin In Advanced NSCLC At WCLC 2015 9/15/2015
Baxalta Files For U.S. Approval Of Investigational 20% Immunoglobulin Subcutaneous (IGSC) Treatment For Primary Immunodeficiency (PI) 9/15/2015
TetraPhase (TTPH) Executive Profits Off Stock Sale Hours Before Company Announces Clinical Trial Failure, Report Says 9/15/2015
Dr. Reddy's Laboratories Ltd. (RDY) Snags Exclusive Rights to Head Lice Product From Hatchtech 9/14/2015
Bayer (BAY) To Showcase Data From Growing Oncology Franchise At ECC2015 In Vienna 9/14/2015
BioLife Solutions, Inc. (BLFS.OB) CryoStor Commercial Grade Freeze Media Embedded In TC Biopharm ImmuniCell Clinical Trial For Various Cancers 9/14/2015
Chimerix (CMRX) And BARDA Announce Contract Extension Of $13.0 Million For The Continued Development Of Brincidofovir For Smallpox 9/14/2015
AbbVie (ABBV) Announces Submission Of A Supplemental New Drug Application For IMBRUVICA (ibrutinib) For Treatment-Naive Chronic Lymphocytic Leukemia 9/14/2015
Janssen Biotech Inc. (JNJ) Release: IMBRUVICA (ibrutinib) Supplemental New Drug Application For Treatment-Naive Chronic Lymphocytic Leukemia Submitted To The U.S. FDA 9/14/2015
Amgen (AMGN) Highlights Key Clinical Data To Be Presented At European Cancer Congress 2015 9/14/2015
Tenax Therapeutics (TENX) Announces First Quarter Fiscal Year 2016 Financial Results 9/14/2015
Innocoll (INNL) CMO Jumps to Pozen (POZN) as Pozen Moves to Ireland 9/14/2015
Laguna Pharmaceuticals Initiates Phase 3 Study Of Vanoxerine In Atrial Fibrillation And Atrial Flutter 9/14/2015
Spark Therapeutics (ONCE) Attempts to Quell Investor’s Nerves About Changes to Clinical Trial 9/11/2015
Array BioPharma, Inc. (ARRY) Announces Clinical Data Presentations At The 2015 European Cancer Congress 9/11/2015
Lori Kunkel, M.D., Joins Tocagen Inc.'s Board Of Directors 9/10/2015
Protagonist Therapeutics Names Richard S. Shames, M.D. As Chief Medical Officer 9/10/2015
Sinovac Biotech Ltd. (SVA) To Participate In Morgan Stanley (MST) Global Healthcare Conference 9/10/2015
pSivida (PSDV) Provides Company Update And Reports Fourth Quarter And FY 2015 Results 9/10/2015
The New England Journal of Medicine (NEJM) Publishes Pivotal Phase 3 Data On Kanuma (Sebelipase Alfa) In Children And Adults With Lysosomal Acid Lipase Deficiency (LAL-D) 9/10/2015